Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:DRUG NASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$3.49$4.10$2.98▼$36.90$25.30M1.26231,725 shs491,783 shsDRUGBright Minds Biosciences$83.50$80.60$23.17▼$123.75$812.62M-5.35226,720 shs281,059 shsRXRXRecursion Pharmaceuticals$3.01$3.28$2.77▼$7.18$1.60B1.0513.52 million shs13.96 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap0.00%+15.56%-10.05%-7.18%-88.63%DRUGBright Minds Biosciences0.00%+7.78%-6.35%-3.47%+187.83%RXRXRecursion Pharmaceuticals0.00%+2.73%-14.25%-11.73%-26.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$3.49$4.10$2.98▼$36.90$25.30M1.26231,725 shs491,783 shsDRUGBright Minds Biosciences$83.50$80.60$23.17▼$123.75$812.62M-5.35226,720 shs281,059 shsRXRXRecursion Pharmaceuticals$3.01$3.28$2.77▼$7.18$1.60B1.0513.52 million shs13.96 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap0.00%+15.56%-10.05%-7.18%-88.63%DRUGBright Minds Biosciences0.00%+7.78%-6.35%-3.47%+187.83%RXRXRecursion Pharmaceuticals0.00%+2.73%-14.25%-11.73%-26.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 1.00SellN/AN/ADRUGBright Minds Biosciences 2.86Moderate Buy$143.8372.26% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10169.10% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, DRUG, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/14/2026RXRXRecursion Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$5.00 ➝ $5.505/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BCTXBriacell Therap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026DRUGBright Minds Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$145.003/30/2026DRUGBright Minds Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$147.003/4/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $145.002/26/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.002/25/2026RXRXRecursion Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$7.00 ➝ $6.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A$9.20 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$23.11 per shareN/ARXRXRecursion Pharmaceuticals$74.68M21.36N/AN/A$1.93 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$26.31M-$23.33N/AN/AN/AN/A-173.08%-139.64%N/ADRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)Latest BCTX, DRUG, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million3/10/2026Q2 2026BCTXBriacell TherapN/A-$2.58N/A-$2.58N/AN/A2/25/2026Q4 2025RXRXRecursion Pharmaceuticals-$0.28-$0.21+$0.07-$0.21$24.56 million$35.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A10.1010.10DRUGBright Minds BiosciencesN/A81.4757.38RXRXRecursion Pharmaceuticals0.015.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%DRUGBright Minds Biosciences40.52%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap0.74%DRUGBright Minds Biosciences42.66%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap87.25 million7.20 millionNo DataDRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableBCTX, DRUG, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24 at 10:10 AM | insidermonkey.comRecursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory?May 24 at 9:16 AM | finance.yahoo.comA Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth ProspectsMay 23 at 11:30 PM | finance.yahoo.comMorgan Stanley Raises its Price Target on Recursion (RXRX)May 22 at 7:49 PM | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.10 Average PT from AnalystsMay 21, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - Here's What HappenedMay 19, 2026 | marketbeat.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | finance.yahoo.comAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CityMay 19, 2026 | globenewswire.comQ4 Earnings Estimate for RXRX Issued By KeyCorpMay 18, 2026 | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by BrokeragesMay 16, 2026 | marketbeat.comRecursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowMay 14, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comRecursion Pharmaceuticals (RXRX) price target decreased by 10.64% to 6.12May 14, 2026 | msn.comRecursion Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 13, 2026 | seekingalpha.comRecursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comVanguard Group Inc. Grows Position in Recursion Pharmaceuticals, Inc. $RXRXMay 11, 2026 | marketbeat.comA Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA DiscussionsMay 9, 2026 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America SecuritiesMay 8, 2026 | theglobeandmail.comRecursion Milestones Link AI Discovery To Clinical And Valuation UpsideMay 8, 2026 | finance.yahoo.comRecursion Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2026 | chron.comRecursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $105,600.00 in StockMay 7, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesLilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentBy Nathan Reiff | May 1, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026BCTX, DRUG, and RXRX Company DescriptionsBriacell Therap NASDAQ:BCTX$3.49 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.50 +0.01 (+0.26%) As of 05/22/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Bright Minds Biosciences NASDAQ:DRUG$83.50 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$83.44 -0.06 (-0.08%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Recursion Pharmaceuticals NASDAQ:RXRX$3.01 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.00 0.00 (-0.17%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
